Comparing two forms of ADL-018 injection in healthy adults

An Open Label, Randomized, Balanced, Two-treatment, Single Period, Parallel, Single Dose, Subcutaneous Administration, Comparative Pharmacokinetic Study of ADL-018 Injection 150 mg/mL Solution in a Single Dose Pre-filled Autoinjector Compared to ADL-018 Injection 150mg/mL Solution in a Single Dose Pre-filled Syringe in Normal, Healthy, Adult Subjects Under Fasting Conditions

This study is testing two different ways to give an injection of ADL-018 to healthy adults to see how the body absorbs it and how safe it is.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 150 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Kashiv BioSciences, LLC (Industry-sponsored)
• Drugs / interventions: Omalizumab
• Locations: 1 site (Missisauga)
• Trial ID: NCT06929052 on ClinicalTrials.gov

What this trial studies

This study aims to compare the pharmacokinetics of ADL-018 Injection delivered via a pre-filled autoinjector versus a pre-filled syringe in healthy adult subjects. It is an open-label, randomized, and balanced study that involves a single dose of the investigational product administered subcutaneously under fasting conditions. The study will also assess the safety and tolerability of the investigational product. Participants will undergo blood sample collection for pharmacokinetic analysis over a period of approximately 127 days.

Who should consider this trial

Good fit: Ideal candidates are healthy adults aged 18 to 65 with specific serum IgE levels.

Not a fit: Patients with chronic idiopathic urticaria or those outside the specified age and health criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved delivery methods for chronic idiopathic urticaria treatments.

How similar studies have performed: While this approach is comparative, similar pharmacokinetic studies have shown success in evaluating drug delivery methods.

Eligibility criteria

Inclusion Criteria:

1. Age: 18 to 65 years of age, inclusive, at the time of dosing.
2. Subject should be having serum total IgE ≤ 100 IU/ml at the time of screening
3. Gender: Male and/or non-pregnant, non-lactating female. Female of childbearing potential must have a negative serum pregnancy test performed within 28 days prior to dosing day.
4. Male subjects and/or female subject's partner must agree to use acceptable form of contraception which includes vasectomy, or use condoms, or spermicide in addition to female contraception for additional protection against conception from screening until 156 days after administration of the study medication.
5. For female of childbearing potential, must agree to use acceptable forms of contraception from screening until 156 days after administration of the

   Investigational Product include the following:

   Non hormonal intrauterine device in place, or Barrier methods containing or used in conjunction with a spermicidal agent, or Surgical sterilization or Practicing sexual abstinence.

   Female will not be considered of childbearing potential if one of the following is reported and documented on the medical history:

   Postmenopausal with spontaneous amenorrhea for at least one year, or Spontaneous amenorrhea for more than 6 months and less than one year with Serum Follicular Stimulating Hormone (FSH) level \> 40 IU/L, or Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or Total hysterectomy and an absence of bleeding for at least 3 months.
6. BMI: 18.5 to 32.0 kg/m2, both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g., 32.04 rounds down to 32.0, while 18.49 rounds up to 18.5).
7. Volunteers having body weight ≥50.0 kg or ≤ 90.0 kg.
8. Able to communicate effectively with study personnel.
9. Willing to provide written informed consent to participate in the study.
10. Non-smokers and non-tobacco users (i.e., having no past history of smoking and tobacco consuming for at least one year prior to study). All volunteers must be judged by the principal and /or sub investigator principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the study medication administration which will include: A comprehensive physical examination, medical history, vital sign assessments, 12-lead electrocardiogram (ECG) with no clinically significant finding.

Exclusion Criteria:

2) History of allergic reactions or sensitivity to latex or latex derived products.

3) Have significant diseases or clinically significant abnormal findings during screening \[medical history, comprehensive physical examination, vital signs, laboratory evaluations and ECG\]. 4) Any disease or condition like diabetes, psychosis or others, which might compromise the hemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system. 5) History of helminthic or parasitic infection. 6) History of immunological disorders or presence of bronchial asthma. 7) Use of any hormone replacement therapy within 3 months prior to the study medication administration. 8) Use of any depot injection or implant of any drug within 3 months prior to the study medication administration.

9) Use of CYP enzyme inhibitors or inducers or St. John's Wort within 30 days prior to the study medication administration (see https://druginteractions. medicine.iu.edu/MainTable.aspx). 10) Reports a history of drug or alcohol addiction or abuse within the past 1 year.

11) History or evidence of drug dependence. 12) History of difficulty with donating blood or difficulty in accessibility of veins.

13) A positive hepatitis screen (hepatitis B surface antigen, hepatitis C antibody).

14) A positive test result for HIV antibody. 15) Demonstrates a positive drug screen, cotinine, or alcohol test during screening 16) Volunteers who have received any investigational drug/product within 30 days prior to the study medication administration.

17) Volunteers who have donated blood or loss of blood between 101 mL to 499 mL within 30 days prior to dosing or a blood donation of more than 499 mL within 56 days prior to dosing for male volunteers and 84 days prior to dosing for female volunteers.

18) Intolerance to venipuncture Demonstrates, in the opinion of the study staff, inadequate vein or vein unsuitable for repeated venipuncture (e.g. vein difficult to locate, access or puncture, vein with a tendency to rupture during or after puncture). 20) Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study. 21) If, in the opinion of the investigator, the subject is not suitable for the study.

22) Institutionalized volunteers. 23) Use of any prescribed medications and/or Monoamine Oxidase Inhibitor (MAOI) within 14 days prior to the study medication administration. 24) Use of any herbal or dietary supplements or over-the-counter medications (Tylenol, Advil, etc.) or therapeutic dose of vitamins (including vitamin water) products, etc., within 7 days prior to the study medication administration. 25) Use of any products containing Seville oranges, grapefruit and pomelo within 7 days prior to the study medication administration.

26) Use of any products containing broccoli, brussels sprouts, and char-grilled meat within 14 days prior to the study medication administration.

27) Ingestion of any caffeine/xanthine containing products (coffee, tea, soft drinks, chocolate, energy drinks, etc.), alcohol and/or other alcohol containing products, foods containing poppy seeds within 48 hours prior to the study medication administration. 28) Ingestion of any beverages containing more than 5% fruit juice (fruit drinks, fruit punches, fruit cocktails, fruit , or other products containing 5% or less of fruit juice will be allowed) within 48 hours prior to the study medication administration. 29) Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the study medication administration.

30) History of anaphylactic shock. 31) History of being on allergy vaccine therapy. 32) Intravenous (IV) immunoglobulin G (IVIG), or plasmapheresis within 90 days prior to the study medication administration.

Subjects with current malignancy, history of malignancy, or currently under work-up for suspected malignancy except non-melanoma skin cancer that has been treated or excised and is considered resolved. 34) Female volunteer who has used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 3 months before dosing.

35) Pregnant, breastfeeding, or intends to become pregnant over the course of the study.

36) Difficulty in fasting or consuming standardized meals. 37) Reports a clinically significant illness during the 28 days prior to dosing (as determined by the investigator and/or designee). 38) Reports undergoing any kind of surgical procedures with general anesthesia within 3 months prior to dosing.

39) Presence of tattoos or other skin conditions on both the left and right upper outer arms at the injection site based on PI discretion.

Where this trial is running

Missisauga

• Not Disclosed — Missisauga, Canada (Recruiting)

Study contacts

• Study coordinator: Dr Pawan Singh, MD,DM Pharmacology

Conditions Chronic Idiopathic Urticaria; Xolair; Urticaria